AOD9604 and fat loss: what the evidence actually shows

What did @daisyfamhealth actually say?

In short: AOD-9604 is a modified fragment of human growth hormone engineered to target fat metabolism without affecting blood sugar or growth. The creator, a nurse practitioner, describes it as supporting "fat burner pathways" when paired with lifestyle habits, and notes it has been studied for obesity, cartilage repair, and inflammation. She also mentions pairing it with GLP-1 protocols in her own practice.

A few specific claims stand out. She says it promotes lipolysis (fat breakdown) while slowing lipogenesis (new fat cell formation), calling that "a powerful combination." She acknowledges the data is "still evolving" and wraps with a standard educational disclaimer. The framing is generally measured, though the caption calling it "strictly for burning fat" is a bit more aggressive than the nuanced language in the actual video.

Does the science back this up?

Partially, yes, but the evidence base is thinner than the peptide's reputation suggests. The most significant published work comes from Metabolic Pharmaceuticals, the Australian company that developed AOD-9604 and ran it through Phase I, II, and III trials in the early 2000s. Those trials showed modest weight loss results and a clean safety profile, but the Phase III trials failed to demonstrate statistically significant weight loss over placebo at the doses tested.

The lipolysis claim has legitimate preclinical support. Heffernan et al. (2001, American Journal of Physiology) showed AOD-9604 stimulated lipolysis and inhibited lipogenesis in rodent fat cells, which is exactly what the creator describes. Whether those mechanisms translate cleanly to meaningful fat loss in humans at practical doses is a different and unresolved question. The cartilage repair angle has some preclinical backing (Ghosh et al., 2007, Osteoarthritis and Cartilage) but calling it an established benefit stretches the data considerably.

What did they get wrong (or right)?

Credit where it is due: the mechanistic explanation is accurate. AOD-9604 is a C-terminal fragment of human growth hormone (hGH 176-191) modified with a disulfide bridge, and the design rationale, removing the IGF-1-stimulating domain while preserving the lipolytic region, is described correctly. Saying it does not affect blood sugar is also consistent with the published safety data.

Where she overstates things: describing existing research as showing it has been studied for obesity "with a surprisingly safe profile so far" glosses over the fact that Phase III obesity trials failed their primary endpoints. Safe is not the same as effective. The lipogenesis inhibition claim is real in cell and animal models, but she presents it as an established human effect, which it is not. The caption "strictly for burning fat" is also flatly reductive given the actual complexity and limitations of the data. And the offhand mention of stacking with GLP-1s, while framed as personal practice, is not supported by any published combination safety or efficacy data.

What should you actually know?

AOD-9604 is not FDA-approved for any indication. It received FDA GRAS (Generally Recognized as Safe) status as a food ingredient in 2014, which is sometimes misrepresented as a broader regulatory endorsement. It is not. In the United States, it is currently available primarily through compounding pharmacies as an unapproved drug, and its regulatory status is actively shifting.

• The human trial data for weight loss is limited and the Phase III results were not positive enough to earn approval.
• Preclinical fat metabolism data is real but animal-to-human translation in peptide research is notoriously inconsistent.
• There is no peer-reviewed human data on combining AOD-9604 with GLP-1 receptor agonists. Stacking two agents that affect metabolic pathways without that data is a clinical unknown, not an established protocol.
• Anyone considering this peptide should be working with a licensed provider who can document informed consent, monitor for adverse effects, and source from a verified compounding pharmacy following USP <797> standards.